Switch theme
Sign up to access all valuation multiples
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
2014
128
LTM Revenue $92.7M
LTM EBITDA -$64.8M
$166M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stoke Therapeutics has a last 12-month revenue (LTM) of $92.7M and a last 12-month EBITDA of -$64.8M.
In the most recent fiscal year, Stoke Therapeutics achieved revenue of $36.6M and an EBITDA of -$99.2M.
Stoke Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stoke Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $92.7M | XXX | $36.6M | XXX | XXX | XXX |
| Gross Profit | $92.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$64.8M | XXX | -$99.2M | XXX | XXX | XXX |
| EBITDA Margin | -70% | XXX | -271% | XXX | XXX | XXX |
| EBIT | -$65.3M | XXX | -$101M | XXX | XXX | XXX |
| EBIT Margin | -70% | XXX | -277% | XXX | XXX | XXX |
| Net Profit | -$53.6M | XXX | -$89.0M | XXX | XXX | XXX |
| Net Margin | -58% | XXX | -243% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Stoke Therapeutics's stock price is $10.
Stoke Therapeutics has current market cap of $521M, and EV of $166M.
See Stoke Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $166M | $521M | XXX | XXX | XXX | XXX | $-0.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Stoke Therapeutics has market cap of $521M and EV of $166M.
Stoke Therapeutics's trades at 4.5x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Stoke Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stoke Therapeutics has a P/E ratio of -9.7x.
See valuation multiples for Stoke Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $521M | XXX | $521M | XXX | XXX | XXX |
| EV (current) | $166M | XXX | $166M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.7x | XXX | -5.9x | XXX | XXX | XXX |
| EV/FCF | -11.1x | XXX | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStoke Therapeutics's last 12 month revenue growth is 23%
Stoke Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.1M for the same period.
Stoke Therapeutics's rule of 40 is -1256% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stoke Therapeutics's rule of X is -13% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Stoke Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | -8% | XXX | XXX | XXX |
| EBITDA Margin | -70% | XXX | -271% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1256% | XXX | -248% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -13% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 244% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 377% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stoke Therapeutics acquired XXX companies to date.
Last acquisition by Stoke Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Stoke Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stoke Therapeutics founded? | Stoke Therapeutics was founded in 2014. |
| Where is Stoke Therapeutics headquartered? | Stoke Therapeutics is headquartered in United States of America. |
| How many employees does Stoke Therapeutics have? | As of today, Stoke Therapeutics has 128 employees. |
| Who is the CEO of Stoke Therapeutics? | Stoke Therapeutics's CEO is Mr. Ian F. Smith. |
| Is Stoke Therapeutics publicy listed? | Yes, Stoke Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Stoke Therapeutics? | Stoke Therapeutics trades under STOK ticker. |
| When did Stoke Therapeutics go public? | Stoke Therapeutics went public in 2019. |
| Who are competitors of Stoke Therapeutics? | Similar companies to Stoke Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Stoke Therapeutics? | Stoke Therapeutics's current market cap is $521M |
| What is the current revenue of Stoke Therapeutics? | Stoke Therapeutics's last 12 months revenue is $92.7M. |
| What is the current revenue growth of Stoke Therapeutics? | Stoke Therapeutics revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Stoke Therapeutics? | Current revenue multiple of Stoke Therapeutics is 1.8x. |
| Is Stoke Therapeutics profitable? | Yes, Stoke Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stoke Therapeutics? | Stoke Therapeutics's last 12 months EBITDA is -$64.8M. |
| What is Stoke Therapeutics's EBITDA margin? | Stoke Therapeutics's last 12 months EBITDA margin is -70%. |
| What is the current EV/EBITDA multiple of Stoke Therapeutics? | Current EBITDA multiple of Stoke Therapeutics is -2.6x. |
| What is the current FCF of Stoke Therapeutics? | Stoke Therapeutics's last 12 months FCF is -$14.9M. |
| What is Stoke Therapeutics's FCF margin? | Stoke Therapeutics's last 12 months FCF margin is -16%. |
| What is the current EV/FCF multiple of Stoke Therapeutics? | Current FCF multiple of Stoke Therapeutics is -11.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
